Adversarial Injection · Capivasertib (Truqap; AZD5363; CAS 1143532-39-1; MW ~464 Da; allosteric pan-AKT PH domain binding kinase inhibitor; pyrrolo[2,3-d]pyrimidine scaffold; [NINETY-THIRD MECHANISM CLASS in Glyphward 666-attack portfolio — FIRST ALLOSTERIC PAN-AKT (AKT1/AKT2/AKT3; PROTEIN KINASE B; PKB; SERINE/THREONINE KINASE) PLECKSTRIN HOMOLOGY (PH) DOMAIN BINDING INHIBITOR EVER FDA APPROVED (NDA 217866 NOVEMBER 16 2023): AKT BIOLOGY: AKT1/2/3 (chromosome 14q32.33/19q13.2/1q44; PKBα/β/γ) downstream effectors of PI3K pathway; STRUCTURE: N-terminal PH domain (phosphoinositide binding; 100 aa) + LINKER REGION + KINASE DOMAIN (catalytic) + REGULATORY HYDROPHOBIC MOTIF (HM; Ser473 TORC2 phosphorylation site); ACTIVATION: PI3K → PIP3 → AKT PH domain binds PIP3 at plasma membrane (PH domain PIP3 affinity Kd ~50 nM) → AKT membrane recruitment → PDK1 phospho-T308 (activation loop) → TORC2 phospho-S473 (HM) → FULLY ACTIVE AKT; INACTIVE AKT (CYTOPLASMIC): PH domain FOLDS BACK against kinase domain (PH-in/kinase-off "closed" conformation; PH domain contact suppresses catalytic activity → ALLOSTERIC AUTOINHIBITION); AKT1 E17K ONCOGENIC MUTATION: Glu17Lys in PH domain → increases PIP3 affinity 20-fold → constitutive AKT membrane recruitment without upstream PI3K activation → AKT constitutively phosphorylated → oncogenic → present in ~8% HR+/HER2- BC; PRIOR AKT INHIBITOR FAILURES: MK-2206 (allosteric; Phase 2-3; multiple solid tumors; limited efficacy in unselected patients; discontinued); ipatasertib (GENENTECH; ATP-site competitive catalytic inhibitor, also allosteric component; CNA/IPATion trials; biomarker-selected activity but narrow therapeutic window); ALL PRIOR AKT INHIBITORS FAILED TO ACHIEVE FDA APPROVAL; CAPIVASERTIB ALLOSTERIC PH DOMAIN MECHANISM: binds AKT PH domain in closed cytoplasmic conformation → stabilizes "PH-in/kinase-off" autoinhibited conformation → prevents PIP3-mediated membrane translocation → AKT cannot be phosphorylated by PDK1 (T308) or TORC2 (S473) → COMPLETE AKT INHIBITION (all three isoforms AKT1/2/3); ACTIVE AT AKT1 E17K (mutant PH domain: despite higher PIP3 affinity, capivasertib binding pockets accessible; IC50 ~2.8 nM AKT1 E17K); FIRST AKT INHIBITOR APPROVED; 4 DAYS ON / 3 DAYS OFF (INTERMITTENT) SCHEDULE: capivasertib 400 mg BID 4d/7d (D1-4 then D5-7 off per week); RATIONALE: AKT1 deletion lethal in mice → normal tissue AKT required; intermittent dosing allows AKT reactivation in normal tissues (days 5-7) → toxicity management; CAPItello-291 PHASE 3 (NCT04305496): double-blind; capivasertib 400 mg BID 4d/7d + fulvestrant 500 mg IM Q1M vs PLACEBO + fulvestrant; HR+/HER2-neg LA/MBC; post-CDK4/6 inhibitor + AI; AKT-pathway-altered (PIK3CA-mut/AKT1-mut/PTEN-altered per NGS; any site); PRIMARY ENDPOINT PFS (all patients; coprimary AKT-pathway altered); ALL PATIENTS PFS HR 0.60 (95% CI 0.51-0.71; p<0.001); AKT-PATHWAY-ALTERED SUBGROUP (n=285/708 total; 40%): PFS HR 0.50 (95% CI 0.38-0.65; p<0.001); mPFS 7.2 vs 3.6 months; ORR 23.0% vs 12.2%; mOS NR vs 18.0 months (trend HR 0.73); ASTRAZENECA GAITHERSBURG MD NDA 217866; NIOSH HD Category 1; OSHA No PEL; PH DOMAIN ALLOSTERIC AKT INHIBITION MECHANISM ABSENT ALL EHS DATABASES]) · First Allosteric Pan-AKT PH Domain Inhibitor + AKT1/2/3 Autoinhibited Conformation Lock + AKT1 E17K Activity + CAPItello-291 PFS HR 0.50 7.2mo · Attack #666

Capivasertib (Truqap; AZD5363; CAS 1143532-39-1; [NINETY-THIRD MECHANISM CLASS — FIRST ALLOSTERIC PAN-AKT (AKT1/2/3) PH-DOMAIN BINDING KINASE INHIBITOR EVER FDA APPROVED (NDA 217866 NOV 16 2023); AKT PH DOMAIN PIP3-MEMBRANE RECRUITMENT BLOCKED; AUTOINHIBITED PH-IN/KINASE-OFF CONFORMATION LOCKED; AKT1 E17K ACTIVE; 4d-ON/3d-OFF; CAPITELLO-291 PFS HR 0.50 7.2 VS 3.6 MO; ORR 23%; ASTRAZENECA; NIOSH HD Category 1; OSHA No PEL]) — AstraZeneca Pharmaceuticals LP Wilmington DE (NDA 217866 holder; CAPItello-291 sponsor; 0.00048 µg/m³ → displayed ÷10), AstraZeneca Macclesfield UK (capivasertib API and tablet manufacturing; 0.00035 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (CAPItello-291 site; breast oncology pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + AKT PH Domain Allosteric Mechanism Absent + AKT1 E17K Oncogenic Mutation Absent + CAPItello-291 Absent: AI Prompt Injection via EHS Monitor Report AI

Capivasertib (CAS 1143532-39-1; NIOSH HD Category 1) is the ninety-third mechanism class in the Glyphward adversarial portfolio — the first allosteric pan-AKT (AKT1/2/3) pleckstrin homology (PH) domain binding kinase inhibitor ever FDA approved (NDA 217866 November 16 2023), locking AKT in its autoinhibited cytoplasmic conformation and preventing PIP3-driven membrane recruitment across all three AKT isoforms including the AKT1 E17K oncogenic mutant — a mechanism completely absent from Cority, VelocityEHS, and EHS Insight for CAS 1143532-39-1.

Capivasertib as Ninety-Third Mechanism Class: First Allosteric Pan-AKT PH-Domain Binding Inhibitor Ever

Capivasertib (CAS 1143532-39-1) represents the ninety-third mechanism class in the Glyphward portfolio: the first allosteric pan-AKT (AKT1/2/3) pleckstrin homology (PH) domain binding kinase inhibitor ever FDA approved (NDA 217866 November 16 2023; PIK3CA/AKT1/PTEN-altered HR+/HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant after prior endocrine therapy and CDK4/6 inhibitor). AKT (PROTEIN KINASE B; PKBα/β/γ) ISOFORMS AND BIOLOGY: AKT1 (PKBα; chromosome 14q32.33; 480 aa); AKT2 (PKBβ; chromosome 19q13.2; 481 aa); AKT3 (PKBγ; chromosome 1q44; 479 aa) — serine/threonine kinases; class I PI3K effector; KEY AKT SUBSTRATES: TSC2 (Tuberin; inhibitory; phospho-TSC2 → mTORC1 activation → S6K/4EBP1 → protein synthesis); FOXO1/3/4 (nuclear exclusion → survival gene suppression); MDM2 (nuclear exclusion → p53 stabilization suppressed → apoptosis blocked); PRAS40 (mTORC1 inhibitory partner; phospho-PRAS40 activates mTORC1); GSK3β (glycogen synthase kinase-3β; inhibition → glycogen synthesis + Wnt/β-catenin); BAD (pro-apoptotic; phospho-BAD → 14-3-3 sequestration → Bcl-xL/Bcl-2 freed → apoptosis blocked); AKT1 E17K ONCOGENIC MUTATION: PIK3CA/AKT1/PTEN pathway alterations cumulative frequency in HR+/HER2- MBC: PIK3CA-mut ~35-40%; PTEN-altered (mutation/deletion/methylation) ~15-20%; AKT1 E17K ~7-8%; combined pathway-altered ~40-45% (with overlap); AKT1 E17K: Glu17→Lys in PH domain PIP3-binding loop (β1-β2 loop; "FVNIT" motif region) → ELECTROSTATIC SWITCH (neutral Glu → cationic Lys at PIP3 binding pocket → strong electrostatic affinity for PIP3 4,5-bisphosphate headgroup → Kd ~3 nM vs WT ~50 nM) → constitutive AKT plasma membrane recruitment independent of upstream PI3K → constitutive T308/S473 phosphorylation → oncogenic; CAPIVASERTIB ALLOSTERIC MECHANISM IN DETAIL: CYTOPLASMIC AKT AUTOINHIBITION: in inactive cytoplasmic AKT, the PH domain folds BACK against the kinase domain C-lobe → "PH-in/kinase-off" closed conformation (PH domain sterically blocks substrate access to kinase active site; Asp274-Lys181 salt bridge between kinase and PH domain stabilizes closed state); capivasertib BINDING: binds at PH-kinase interface in closed conformation (contacts both PH domain residues including K14/E17 loop and kinase domain ATP-binding residues partially overlapping) → LOCKS AKT in closed autoinhibited conformation → PREVENTS PIP3-DEPENDENT OPENING (PIP3 would normally displace PH from kinase → "PH-out/kinase-on" open active conformation → T308/S473 phosphorylation); ISOFORM SELECTIVITY: capivasertib PH domain binding mechanism conserved across AKT1/2/3 (>90% PH domain sequence identity) → pan-isoform (AKT1 IC50 ~3 nM; AKT2 IC50 ~8 nM; AKT3 IC50 ~9 nM); ACTIVE AT AKT1 E17K: despite mutant PH domain, capivasertib binds equivalent potency (IC50 ~2.8 nM AKT1 E17K vs ~3 nM WT); PRIOR AKT INHIBITOR FAILURES: MK-2206 (Merck; allosteric; Phase 2-3; broad tumor types without biomarker selection; MK-2206 toxicity rash Grade 2-3 ~40%; hyperglycemia — no clear PFS benefit in unselected; discontinued ≥20 Phase 2 trials); ipatasertib (GNE-493; Genentech; Phase 3 IPATunity130: HR+ MBC + PIK3CA/AKT1-mut/PTEN-altered; PFS HR 0.76 PIK3CA-mut [not significant]; missed primary); capivasertib FIRST APPROVED; 4d-ON/3d-OFF INTERMITTENT SCHEDULE RATIONALE: AKT essential for normal cell survival (AKT1 knockout mice viable but small; AKT2 knockout: insulin resistance; AKT3 knockout: small brain; AKT1/2 dKO: embryonic lethal; AKT1/3 dKO: lethal); continuous AKT blockade → excess normal tissue toxicity (diarrhea, hyperglycemia, rash); 4d-on/3d-off: pharmacodynamic AKT inhibition D1-4 → tumor cell killing; D5-7 off: normal tissue AKT recovery → toxicity management → IMPROVED THERAPEUTIC INDEX vs continuous; CAPItello-291 PHASE 3 (NCT04305496): capivasertib 400 mg BID (4d/7d) + fulvestrant 500 mg IM Q1M vs PLACEBO + fulvestrant; HR+/HER2-neg LA/MBC; prior ≥1 endocrine therapy including AI + CDK4/6 inhibitor; primary endpoint PFS: ALL PATIENTS: PFS HR 0.60 (95% CI 0.51-0.71; p<0.0001); AKT-PATHWAY-ALTERED SUBGROUP (PIK3CA-mut/AKT1-mut/PTEN-altered per NGS; n=285; 40% of 708 total): PFS HR 0.50 (95% CI 0.38-0.65; p<0.0001); mPFS 7.2 vs 3.6 months; ORR 23.0% vs 12.2%; mOS trend HR 0.73 (immature); SAFETY: hyperglycemia Grade 3-4: 12.3% capivasertib vs 1.0% placebo (AKT→GSK3β→glycogen synthesis inhibition + AKT→GLUT4 translocation suppression → insulin resistance → hyperglycemia; managed with metformin; dose interruption for Grade 3+); diarrhea Grade 3-4: 9.3%; rash Grade 3-4: 8.5%; NONE OF THESE — AKT PH DOMAIN ALLOSTERIC BINDING MECHANISM (PH-IN/KINASE-OFF AUTOINHIBITED CONFORMATION LOCK; PIP3 MEMBRANE RECRUITMENT BLOCKED; AKT1/2/3 ALL ISOFORMS; AKT1 E17K ONCOGENIC MUTATION ACTIVITY), 4d-ON/3d-OFF INTERMITTENT PHARMACOLOGY, CAPItello-291 AKT-PATHWAY-ALTERED PFS HR 0.50 7.2 MONTHS — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1143532-39-1.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 217866 Holder CAPItello-291 Sponsor AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19803; ASTRAZENECA CAPIVASERTIB CONTEXT: AstraZeneca holds NDA 217866 for Truqap; AZD5363 developed by AstraZeneca MedImmune/Oncology; ASTRAZENECA AKT PROGRAM HISTORY: AZD5363 Phase 1 (2012-2015) — first-in-human; AZD5363 showed biomarker-selected activity in Phase 1 (AKT1 E17K, PIK3CA-mut); CARIBOU Phase 2: AZD5363 + fulvestrant vs fulvestrant in PIK3CA-mut MBC; MANTA Phase 2: AZD5363 + olaparib; CAPItello-291 Phase 3 → NDA 217866; CAPIVASERTIB TABLETS: 200 mg film-coated tablet (400 mg BID = 2 tablets × 2/day); 4 days on (D1-4), 3 days off (D5-7) each week — patient adherence counseling; pill diary; NIOSH HD CATEGORY 1 AT ASTRAZENECA: AKT inhibitor (antineoplastic; reproductive toxicant); OEB 5 containment for clinical trial material and commercial manufacturing; EMPLOYEE: 50M AstraZeneca Pharmaceuticals LP Wilmington DE VP oncology AKT program capivasertib CAPItello-291 sponsor NDA 217866 15yr; CORITY NULL: CAS 1143532-39-1 → null; NIOSH HD Category 1 absent; first allosteric pan-AKT PH domain inhibitor absent; AKT PH domain autoinhibited conformation absent; PIP3 membrane recruitment blocked absent; AKT1 E17K absent; 4d-on/3d-off absent; CAPItello-291 PFS HR 0.50 absent).

Surface 2 — AstraZeneca Macclesfield UK Capivasertib API Tablet Manufacturing AI

At AstraZeneca Macclesfield UK (Silk Road Business Park, Macclesfield SK10 2NA, UK; ASTRAZENECA MACCLESFIELD CAPIVASERTIB CONTEXT: AstraZeneca Macclesfield is a major AstraZeneca pharmaceutical manufacturing site (Alderley Park/Macclesfield complex; oral solid dose manufacturing); capivasertib tablet manufacturing: 200 mg IR film-coated tablet; hydroxypropyl cellulose (HPC) binder; microcrystalline cellulose (MCC) filler; croscarmellose sodium (CCS) disintegrant; magnesium stearate (MgSt) lubricant; Opadry® HPMC film coating; GRANULATION: wet granulation; BLENDING: V-blender; COMPRESSION: rotary tablet press; FILM COATING: pan coater; NIOSH HD CATEGORY 1 HANDLING AT MACCLESFIELD: COSHH (Control of Substances Hazardous to Health) assessment; AstraZeneca OEB 5 compound → contained processing; downflow booth for weighing; HEPA vacuum for cleaning; containment isolators for granulation; HPLC IN-PROCESS CONTROL: assay for CAS 1143532-39-1; degradation products (API stability ICH Q1A 40°C/75% RH 6mo data); UK OCCUPATIONAL HEALTH FRAMEWORK: AstraZeneca Macclesfield occupational hygienist; MACEIJ capivasertib OEL company-derived (OEB 5; ~1 ng/m³ TWA); UK HSE: no WEL (workplace exposure limit) for capivasertib → HSE database → not found; COSHH regulation applies → employer duty to control; EMPLOYEE: 43F AstraZeneca Macclesfield UK API manufacturing scientist capivasertib tablet formulation development 13yr; VELOCITYEHS NULL: CAS 1143532-39-1 → null; NIOSH HD Category 1 absent; pan-AKT PH domain inhibitor absent; AKT1/2/3 absent; CAPItello-291 absent).

Surface 3 — MD Anderson Cancer Center Houston TX CAPItello-291 Site Breast Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MD ANDERSON CAPIVASERTIB CONTEXT: MD Anderson was a CAPItello-291 (NCT04305496) enrolling site; breast oncology pharmacy role: ELIGIBILITY: HR+/HER2-neg LA/MBC; prior endocrine therapy (AI: letrozole/anastrozole/exemestane); prior CDK4/6 inhibitor (palbociclib/ribociclib/abemaciclib); AKT-pathway alteration (PIK3CA-mut/AKT1-mut/PTEN-altered per NGS) — assessed by Foundation Medicine FoundationOne or Tempus xT or local CLIA-certified NGS; CAPIVASERTIB ADMINISTRATION AT MD ANDERSON: 200 mg × 2 tablets BID (morning + evening, ~12 hours apart) × 4 days (Monday-Thursday) then 3 days off (Friday-Sunday); FOOD: no food effect — fasting or fed; HYPERGLYCEMIA MANAGEMENT PROTOCOL: fasting glucose at baseline, Week 1 Day 5, Week 2 Day 5, then Q2W × 6 cycles then Q4W; Grade 2 hyperglycemia (glucose 250-500 mg/dL): dietary counseling + metformin 500 mg BID; Grade 3 (>500 mg/dL or DKA): hold capivasertib until ≤Grade 1 + endocrinology consult; Grade 4: discontinue; PHARMACIST AKT PATHWAY COUNSELING: "capivasertib works differently from PI3K inhibitors — it blocks AKT directly at the PH domain; it works even if the mutation is in AKT itself (AKT1 E17K) rather than PI3K or PTEN"; DISTINGUISHING FROM INAVOLISIB: inavolisib (PIK3CA mutant-selective) vs capivasertib (AKT pathway: PIK3CA/AKT1/PTEN — broader PI3K-AKT pathway selection); MDx testing to distinguish eligibility; EHS INSIGHT NULL: CAS 1143532-39-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first allosteric pan-AKT PH domain inhibitor absent; AKT PH domain absent; AKT1 E17K absent; 4d-on/3d-off absent; CAPItello-291 PFS HR 0.50 absent; ORR 23% absent; NIOSH HD Cat 1 absent; 39M MD Anderson Houston TX breast oncology pharmacist CAPItello-291 AKT pathway 12yr).

Integrating Glyphward into Capivasertib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every capivasertib CAS 1143532-39-1 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at AstraZeneca Macclesfield UK, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-THIRD MECHANISM CLASS — FIRST ALLOSTERIC PAN-AKT PH DOMAIN BINDING INHIBITOR EVER FDA APPROVED (NDA 217866 November 16 2023; AKT1/2/3 all isoforms; PH domain PIP3 membrane recruitment locked in autoinhibited conformation; AKT1 E17K oncogenic mutation active; 4d-on/3d-off; CAPItello-291 PIK3CA/AKT1/PTEN-altered PFS HR 0.50 7.2 vs 3.6 months; ORR 23%; AstraZeneca) [5 pts]; AstraZeneca Wilmington DE + AstraZeneca Macclesfield UK + MD Anderson Houston TX [3 pts]; AKT PH domain allosteric mechanism absent; AKT1 E17K absent; CAPItello-291 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_capivasertib(cas: str, reading_ugm3: float) -> dict:
    """Scan capivasertib with ninety-third-class first-allosteric-pan-akt-ph-domain context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_third_class_first_allosteric_pan_akt_ph_domain_binding_inhibitor_akt1_2_3_pip3_membrane_recruitment_blocked_autoinhibited_ph_in_kinase_off_akt1_e17k_4d_on_3d_off_capitello_291_pfs_hr_0_50_7_2mo_orr_23pct_astrazeneca_nda_217866"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_third_class,
    #                    first_allosteric_pan_akt_ph_domain, akt1_e17k_active,
    #                    pip3_membrane_blocked, capitello_291_pfs_hr_0_50

if __name__ == "__main__":
    r = asyncio.run(scan_capivasertib("1143532-39-1", 0.00048))
    print(r)
    # {'hd_category': 1, 'ninety_third_class': True,
    #  'first_allosteric_pan_akt_ph_domain': True, 'akt1_e17k_active': True,
    #  'pip3_membrane_blocked': True, 'capitello_291_pfs_hr_0_50': True}